A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)

drug protocol number
D5982C00008
drug sponsor
AstraZeneca
drug study
Budesonide, Glycopyrronium and Formoterol Fumarate
drug trial site
King Abdulaziz University Hospital (Jeddah)
drug status
Ongoing
drug phase